What is Anixa Biosciences, Inc.'s earnings per share (EPS)?

Anixa Biosciences, Inc. (ANIX) reported diluted earnings per share of -$0.34 for fiscal year 2025. This represents a 12.8% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Anixa Biosciences, Inc. (ANIX) Financials

ANIX

FY2025 annual

Revenue Not reported for FY2025

Net Income -$10.9M +13.0% YoY

EPS (Diluted) -$0.34 +12.8% YoY

Operating Cash Flow -$7.2M +2.2% YoY

Market Cap $100.8M as of Oct 10, 2026

Price / Sales n/m no revenue reported

Price / Earnings n/m net loss, so no earnings multiple, FY2025

Price / Book 7.0x on $14.5M equity, Q3 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 10, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q3 FY2026, ended Jul 31, 2026 Reported Sep 9, 2026 Currency USD FYE October

Newest figures come from the 10-Q for Q3 FY2026, filed Sep 9, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the ANIX SEC filings page.

This page shows Anixa Biosciences, Inc. (ANIX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI ANIX FY2025 2026-10-04

Anixa remains a development-stage business: spending substantially exceeds revenue, losses persist, and outside financing supports operations.

In FY2025, the net loss narrowed to $10.9M from $12.6M, but operating cash flow remained negative at -$7.2M versus -$7.3M in FY2024. The modest cash improvement alongside the larger accounting improvement suggests reduced reported expenses have not materially changed the cash demands of development.

FY2024 revenue was only $210K against $6.4M of research and development, or roughly 30.5x revenue. That relationship describes a business whose financial engine is still investment in development rather than commercial sales.

Total assets fell from $21.6M in FY2024 to $16.1M in FY2025 while liabilities remained comparatively small; meanwhile, debt-to-equity rose to 0.1x from 0.1x. Continued financing inflows alongside negative operating cash flow indicate that available resources are being replenished externally, while the reported liquidity comparison was 25.4 months of the latest annual operating outflow.

Financial Health Signals

Financial health score not available

Anixa Biosciences, Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Piotroski F-Score Partial

1/6

Anixa Biosciences, Inc. passes 1 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).

Earnings Quality No Cash Backing

N/A

Anixa Biosciences, Inc. reported a net loss of $10.9M while operations used $7.2M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Key Financial Metrics

Export CSV

Earnings & Revenue

Net Income

-$2.6M

YoY-15.4%

QoQ-3.6%

Anixa Biosciences, Inc. reported -$2.6M in net income in Q3 2026. This represents a decrease of 15.4% from the same quarter a year earlier. Against the prior quarter it is down 3.6%.

EPS (Diluted)

-$0.08

YoY-14.3%

QoQ-14.3%

Anixa Biosciences, Inc. earned -$0.08 per diluted share (EPS) in Q3 2026. This represents a decrease of 14.3% from the same quarter a year earlier. Against the prior quarter it is down 14.3%.

Revenue

Not reported for Q3 2026.

EBITDA

Not reported for Q3 2026.

Cash & Balance Sheet

Cash & Debt

$1.4M

YoY-6.5%

QoQ-5.3%

5Y CAGR-44.8%

10Y CAGR-3.8%

Anixa Biosciences, Inc. held $1.4M in cash as of Q3 2026; long-term debt is not reported for that period.

Shares Outstanding

35M

YoY+5.6%

QoQ+2.2%

5Y CAGR+3.0%

10Y CAGR+14.8%

Anixa Biosciences, Inc. had 35M shares outstanding in Q3 2026. This represents an increase of 5.6% from the same quarter a year earlier. Against the prior quarter it is up 2.2%.

Free Cash Flow

Not reported for Q3 2026.

Dividends Per Share

Not reported for Q3 2026.

Margins & Returns

Return on Equity

-18.0%

YoY-4.4pp

QoQ-0.6pp

Anixa Biosciences, Inc.'s ROE was -18.0% in Q3 2026, measuring profit generated per dollar of shareholder equity. This is down 4.4 percentage points from the same quarter a year earlier. Against the prior quarter it is down 0.6 percentage points.

Gross Margin

Not reported for Q3 2026.

Operating Margin

Not reported for Q3 2026.

Net Margin

Not reported for Q3 2026.

Capital Allocation

R&D Spending

$1.3M

YoY+25.7%

QoQ+5.4%

Anixa Biosciences, Inc. invested $1.3M in research and development in Q3 2026. This represents an increase of 25.7% from the same quarter a year earlier. Against the prior quarter it is up 5.4%.

Share Buybacks

Not reported for Q3 2026.

Capital Expenditures

Not reported for Q3 2026.

ANIX Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

ANIX quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Revenue	N/A	N/A	$210K0.0%	$210K	N/A	$512K	N/A	$250K-77.5%	$1.1M+206.9%	$363K+20.8%	$300K-96.8%	$9.3M+152.4%	$3.7M+843.1%	$389K-58.6%	$940K-6.3%	$1.0M
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$4K-88.6%	$34K
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$936K-3.4%	$969K
R&D Expenses	N/A	$5.1M-20.7%	$6.4M+34.1%	$4.8M-28.9%	$6.7M+8.3%	$6.2M+41.3%	$4.4M-20.0%	$5.5M-19.7%	$6.8M+326.5%	$1.6M+2.6%	$1.6M+118.8%	$711K	N/A	N/A	$2.2M-29.2%	$3.1M
SG&A Expenses	N/A	$6.6M-10.8%	$7.4M+18.2%	$6.3M-12.3%	$7.2M+1.4%	$7.1M+26.4%	$5.6M-1.2%	$5.7M-18.1%	$6.9M+56.7%	$4.4M+62.8%	$2.7M-50.9%	$5.5M-14.0%	$6.4M-19.8%	$8.0M+179.1%	$2.9M-0.3%	$2.9M
Operating Income	N/A	-$11.7M+15.4%	-$13.8M-25.6%	-$11.0M+20.6%	-$13.9M-5.6%	-$13.1M-31.6%	-$10.0M+16.1%	-$11.9M+16.8%	-$14.3M-135.2%	-$6.1M-34.7%	-$4.5M-377.3%	-$945K+81.3%	-$5.0M+36.3%	-$7.9M-91.5%	-$4.1M+17.8%	-$5.0M
EBITDA	N/A	N/A	N/A	N/A	N/A	N/A	-$9.9M+13.0%	-$11.4M+19.9%	-$14.3M-136.6%	-$6.0M-34.8%	-$4.5M-380.1%	-$932K	N/A	N/A	-$4.1M+17.8%	-$5.0M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$500K-3.7%	$520K+15.1%	$452K-64.2%	$1.3M+13.9%	$1.1M+14377.0%	$8K	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$600K
Net Income	N/A	-$10.9M+13.0%	-$12.6M-28.0%	-$9.8M+27.8%	-$13.6M-4.9%	-$13.0M-29.3%	-$10.0M+14.0%	-$11.6M+16.8%	-$14.0M-179.4%	-$5.0M+0.1%	-$5.0M-263.8%	-$1.4M+85.6%	-$9.6M+4.7%	-$10.1M-137.0%	-$4.3M+42.4%	-$7.4M
EPS (Basic)	N/A	-$0.34+12.8%	-$0.39-21.9%	-$0.32-171.1%	$0.45+200.0%	-$0.45	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EPS (Diluted)	-$0.32	-$0.34+12.8%	-$0.39-21.9%	-$0.32-171.1%	$0.45	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Diluted Shares (Avg)	N/A	32,454+1.7%	31,898+3.0%	30,980+2.0%	30,374-99.9%	29M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'2610-Q	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K
R&D Expenses	$1.3M+25.7%	$1.3M-4.8%	$1.1M-29.0%	N/A	$1.1M-45.2%	$1.3M-19.7%	$1.6M+15.0%	N/A
SG&A Expenses	$1.4M+2.2%	$1.4M-17.4%	$1.6M-12.0%	N/A	$1.4M-17.2%	$1.7M-7.7%	$1.8M-18.8%	N/A
Operating Income	-$2.7M-12.4%	-$2.6M+11.9%	-$2.7M+19.8%	N/A	-$2.4M+32.2%	-$3.0M+13.4%	-$3.4M+6.2%	N/A
Net Income	-$2.6M-15.4%	-$2.5M+9.8%	-$2.6M+19.4%	N/A	-$2.3M+31.1%	-$2.8M+11.1%	-$3.2M+2.2%	N/A
EPS (Basic)	-$0.08-14.3%	-$0.07+22.2%	-$0.08+20.0%	-$0.090.0%	-$0.07+30.0%	-$0.09+10.0%	-$0.100.0%	-$0.090.0%
EPS (Diluted)	-$0.08-14.3%	-$0.07+22.2%	-$0.08+20.0%	-$0.090.0%	-$0.07+30.0%	-$0.09+10.0%	-$0.100.0%	-$0.090.0%
Diluted Shares (Avg)	34M+5.3%	34M+4.3%	33M+3.2%	N/A	32M+1.3%	32M+0.9%	32M+2.4%	N/A

Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, EBITDA, Interest Expense, Income Tax.

ANIX Balance Sheet

ANIX quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Total Assets	$16.1M-25.5%	$21.6M-15.4%	$25.5M-16.1%	$30.4M-16.1%	$36.3M+283.6%	$9.5M+50.2%	$6.3M-2.4%	$6.4M-26.8%	$8.8M+56.6%	$5.6M-39.7%	$9.3M+3.1%	$9.1M+66.5%	$5.4M-3.9%	$5.7M-34.5%	$8.6M
Current Assets	$15.9M-25.6%	$21.4M-15.8%	$25.4M-16.0%	$30.2M-16.1%	$36.0M+284.3%	$9.4M+53.8%	$6.1M+10.0%	$5.5M-21.0%	$7.0M+106.3%	$3.4M-50.7%	$6.9M+9.1%	$6.3M+412.4%	$1.2M+33.8%	$922K-70.5%	$3.1M
Cash & Equivalents	$1.2M-2.1%	$1.3M+38.9%	$915K-92.6%	$12.4M-57.6%	$29.1M+353.9%	$6.4M+83.8%	$3.5M+14.3%	$3.1M-8.5%	$3.3M+34.2%	$2.5M-43.0%	$4.4M+30.0%	$3.4M+274.2%	$898K+164.4%	$340K-56.1%	$774K
Short-Term Investments	$13.9M-25.3%	$18.7M-18.6%	$22.9M+32.3%	$17.3M+162.6%	$6.6M+150.0%	$2.6M+12.3%	$2.4M+17.5%	$2.0M-42.9%	$3.5M+366.7%	$750K-68.8%	$2.4M-4.0%	$2.5M	$0-100.0%	$500K-77.8%	$2.2M
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$400K+128.6%	$175K+2400.0%	$7K	N/A
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0-100.0%	$4.2M-11.2%	$4.7M-12.1%	$5.4M
Total Liabilities	$2.1M-21.2%	$2.7M+25.7%	$2.2M-2.8%	$2.2M+48.5%	$1.5M+25.4%	$1.2M-19.8%	$1.5M+46.1%	$1.0M+14.0%	$889K-80.8%	$4.6M+8.4%	$4.3M-15.1%	$5.0M-42.4%	$8.8M+27.8%	$6.9M-9.7%	$7.6M
Current Liabilities	$2.0M-21.3%	$2.5M+23.3%	$2.0M-0.4%	$2.0M+60.4%	$1.3M+6.8%	$1.2M-19.8%	$1.5M	N/A	$889K+89.8%	$469K-21.1%	$594K-67.2%	$1.8M-43.7%	$3.2M+76.2%	$1.8M-13.4%	$2.1M
Non-Current Liabilities	$163K-19.7%	$203K+65.0%	$123K-29.7%	$175K-20.5%	$220K	$0	$0+100.0%	-$251K	$0-100.0%	$4.2M+13.1%	$3.7M+14.0%	$3.2M-41.7%	$5.5M+10.3%	$5.0M-8.2%	$5.5M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$370K	N/A	N/A	N/A	N/A
Total Equity	$15.2M-24.2%	$20.0M-17.8%	$24.3M-16.2%	$29.0M-18.0%	$35.4M+304.5%	$8.8M+67.3%	$5.2M-3.7%	$5.4M-31.4%	$7.9M+702.3%	$987K-80.5%	$5.1M+26.0%	$4.0M+220.7%	-$3.3M-178.1%	-$1.2M-212.9%	$1.1M
Retained Earnings	-$251.7M-4.5%	-$240.8M-5.5%	-$228.2M-4.5%	-$218.4M-6.6%	-$204.8M-6.8%	-$191.8M-5.5%	-$181.8M-6.8%	-$170.2M-9.0%	-$156.2M-3.3%	-$151.2M-3.4%	-$146.1M-1.0%	-$144.8M-7.1%	-$135.2M-8.1%	-$125.1M-3.5%	-$120.8M

Metric	Q3'2610-Q	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K
Total Assets	$15.1M-14.6%	$14.9M-12.4%	$15.2M-19.4%	$16.1M-25.5%	$17.7M-22.9%	$17.0M-30.3%	$18.9M-25.5%	$21.6M-15.4%
Current Assets	$14.9M-14.5%	$14.7M-12.4%	$15.1M-19.5%	$15.9M-25.6%	$17.4M-23.0%	$16.8M-30.8%	$18.7M-25.9%	$21.4M-15.8%
Cash & Equivalents	$1.4M-6.5%	$1.5M-22.7%	$1.5M+46.9%	$1.2M-2.1%	$1.5M+22.0%	$1.9M+92.0%	$1.1M+5.5%	$1.3M+38.9%
Short-Term Investments	$12.5M-14.2%	$12.2M-10.8%	$12.7M-21.9%	$13.9M-25.3%	$14.5M-25.5%	$13.7M-38.5%	$16.2M-28.9%	$18.7M-18.6%
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$1.9M-16.4%	$1.6M-20.8%	$1.4M-36.8%	$2.1M-21.2%	$2.2M+1.0%	$2.1M+16.7%	$2.2M+24.0%	$2.7M+25.7%
Current Liabilities	$1.7M-15.5%	$1.5M-20.5%	$1.2M-38.2%	$2.0M-21.3%	$2.1M+3.1%	$1.9M+12.3%	$2.0M+20.4%	$2.5M+23.3%
Non-Current Liabilities	$128K-26.4%	$140K-23.9%	$151K-22.2%	$163K-19.7%	$174K-18.3%	$184K+97.8%	$194K+79.6%	$203K+65.0%
Total Equity	$14.5M-12.8%	$14.5M-9.9%	$15.1M-15.5%	$15.2M-24.2%	$16.6M-23.8%	$16.1M-32.0%	$17.9M-27.4%	$20.0M-17.8%
Retained Earnings	-$259.4M-4.2%	-$256.8M-4.1%	-$254.2M-4.2%	-$251.7M-4.5%	-$249.0M-4.7%	-$246.7M-5.2%	-$243.9M-5.4%	-$240.8M-5.5%

Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.

ANIX Cash Flow Statement

ANIX quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Operating Cash Flow	-$7.4M	-$7.2M+2.2%	-$7.3M-18.1%	-$6.2M+4.4%	-$6.5M-31.5%	-$4.9M+20.0%	-$6.2M-30.2%	-$4.7M-11.0%	-$4.3M-12.6%	-$3.8M-12.3%	-$3.4M-348.0%	$1.4M+157.3%	-$2.4M+25.3%	-$3.2M-1.5%	-$3.1M-338.7%	-$716K
Depreciation & Amortization	N/A	N/A	N/A	N/A	N/A	N/A	$38K-91.8%	$466K+2429.5%	$18K-57.3%	$43K+29.6%	$33K+166.3%	$13K	N/A	N/A	$7K-9.3%	$8K
Stock-Based Compensation	N/A	$3.7M-16.7%	$4.4M0.0%	$4.4M-26.3%	$6.0M-20.0%	$7.5M+91.3%	$3.9M+168.7%	-$5.7M+35.8%	-$8.9M-430.5%	-$1.7M	N/A	$2.7M+25.8%	$2.1M-21.0%	$2.7M+190.5%	$927K-49.0%	$1.8M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	$16K-91.0%	$175K+356.9%	$38K+27.2%	$30K-79.4%	$147K+167.5%	$55K+719.5%	$7K	N/A	$2K-82.3%	$9K
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	-$6.2M-25.9%	-$4.9M-14.0%	-$4.3M-12.7%	-$3.8M-8.5%	-$3.5M-369.6%	$1.3M+154.8%	-$2.4M	N/A	-$3.1M-333.4%	-$725K
Investing Cash Flow	$2.1M	$4.9M+13.8%	$4.3M+176.3%	-$5.6M+47.8%	-$10.7M-173.9%	-$3.9M-1180.9%	-$306K+41.8%	-$525K-136.0%	$1.5M+153.4%	-$2.7M-281.9%	$1.5M+3224.5%	$45K+101.8%	-$2.5M-602.0%	$499K-71.4%	$1.7M+181.7%	-$2.1M
Financing Cash Flow	$5.2M	$2.3M-33.2%	$3.4M+833.1%	$366K-19.0%	$452K-98.6%	$31.6M+235.6%	$9.4M+65.0%	$5.7M+125.5%	$2.5M-65.8%	$7.4M+275995.0%	-$3K+99.3%	-$401K-105.5%	$7.3M+126.4%	$3.2M+238.7%	$958K-62.2%	$2.5M
Share Buybacks	N/A	N/A	$6K	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'2610-Q	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K
Operating Cash Flow	-$1.8M-17.1%	-$1.7M-15.8%	-$2.6M+10.1%	-$1.3M-35.4%	-$1.5M+42.8%	-$1.5M-3.2%	-$2.9M-25.8%	-$927K+52.9%
Stock-Based Compensation	N/A	N/A	$768K-25.5%	N/A	N/A	N/A	$1.0M-6.9%	N/A
Investing Cash Flow	-$245K+70.6%	$422K-82.0%	$1.2M-54.6%	$654K-24.6%	-$833K-130.6%	$2.3M+321.2%	$2.7M+1995.3%	$867K+246.2%
Financing Cash Flow	$1.9M+0.4%	$1.2M+6838.9%	$1.7M+10011.8%	$350K+230.2%	$1.9M+1194.6%	$18K-98.0%	-$17K-100.8%	$106K-62.0%

Not reported in any period shown, so not listed: Depreciation & Amortization, Capital Expenditures, Free Cash Flow, Dividends Paid, Share Buybacks.

ANIX Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

ANIX quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	99.6%+3.0pp	96.6%
Operating Margin	N/A	-6586.2%	-5243.3%	N/A	-2565.6%	N/A	-4756.0%	-1284.4%	-1676.0%	-1503.0%	-10.2%	-137.5%	-2036.2%	-439.8%	-501.2%
Net Margin	N/A	-5978.1%	-4671.9%	N/A	-2530.1%	N/A	-4658.8%	-1258.1%	-1381.8%	-1672.1%	-14.9%	-261.9%	-2592.3%	-452.4%	-735.5%
Return on Equity	-72.1%-9.3pp	-62.8%-22.5pp	-40.3%+6.5pp	-46.8%-10.3pp	-36.5%+77.8pp	-114.3%+108.1pp	-222.5%+35.1pp	-257.5%-194.3pp	-63.2%+444.8pp	-508.0%-480.7pp	-27.3%+212.3pp	-239.6%	N/A	N/A	-697.3%
Return on Assets	-68.0%-9.8pp	-58.1%-19.7pp	-38.4%+6.3pp	-44.7%-9.0pp	-35.7%+70.3pp	-106.0%+79.1pp	-185.1%+32.0pp	-217.0%-160.2pp	-56.8%+32.3pp	-89.1%-74.4pp	-14.8%+91.3pp	-106.1%+79.2pp	-185.3%-110.2pp	-75.1%+10.2pp	-85.3%
Current Ratio	8.08-0.5x	8.54-4.0x	12.50-2.3x	14.83-13.5x	28.35+20.5x	7.88+3.8x	4.11	N/A	7.89+0.6x	7.25-4.4x	11.61+8.1x	3.49+3.1x	0.38-0.1x	0.51-1.0x	1.48
Debt-to-Equity	0.140.0x	0.140.0x	0.090.0x	0.080.0x	0.04-0.1x	0.14-0.1x	0.28+0.1x	0.19+0.1x	0.11-4.6x	4.70+4.6x	0.07-1.2x	1.26	N/A	N/A	7.17
Asset Turnover	N/A	0.010.0x	0.01	N/A	0.01	N/A	0.04-0.1x	0.17+0.1x	0.040.0x	0.05-0.9x	0.99+0.6x	0.41+0.3x	0.07-0.1x	0.17+0.1x	0.12
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	-1966.8%	-387.6%	-1055.7%	-1176.1%	14.1%+79.2pp	-65.1%	N/A	-334.3%	-72.3%

Metric	Q3'2610-Q	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K
Return on Equity	-18.0%-4.4pp	-17.4%0.0pp	-17.0%+0.8pp	N/A	-13.6%+1.4pp	-17.4%-4.1pp	-17.8%-4.6pp	N/A
Return on Assets	-17.3%-4.5pp	-16.9%-0.5pp	-16.8%0.0pp	N/A	-12.8%+1.5pp	-16.4%-3.5pp	-16.8%-4.0pp	N/A
Current Ratio	8.54+0.1x	9.79+0.9x	12.18+2.8x	8.08-0.5x	8.45-2.9x	8.88-5.5x	9.35-5.8x	8.54-4.0x
Debt-to-Equity	0.130.0x	0.110.0x	0.090.0x	0.140.0x	0.140.0x	0.13+0.1x	0.12+0.1x	0.140.0x

Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Asset Turnover, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
Anixa Biosciences, Inc. ANIX	FY2025	N/A	-$10.9M	N/A	$100.8M	—
TScan Therapeutics, Inc. TCRX	FY2025	$10.3M	-$129.8M	N/A	$16.1M	38/100
Surrozen, Inc. SRZN	FY2025	$3.5M	-$242.0M	N/A	$349.0M	42/100
Shattuck Labs, Inc. STTK	FY2025	$1.0M	-$48.8M	N/A	$599.2M	59/100
Pyxis Oncology, Inc. PYXS	FY2025	$13.9M	-$79.6M	N/A	$169.3M	56/100
Adagene Inc. ADAG	FY2025	$7.7M	-$17.6M	N/A	$185.3M	63/100

Where Anixa Biosciences, Inc. Ranks

Frequently Asked Questions

Is Anixa Biosciences, Inc. profitable?

No, Anixa Biosciences, Inc. (ANIX) reported a net income of -$10.9M in fiscal year 2025.

What is Anixa Biosciences, Inc.'s return on equity (ROE)?

Anixa Biosciences, Inc. (ANIX) has a return on equity of -72.1% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Anixa Biosciences, Inc.'s operating cash flow?

Anixa Biosciences, Inc. (ANIX) recorded an outflow of $7.2M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are Anixa Biosciences, Inc.'s total assets?

Anixa Biosciences, Inc. (ANIX) had $16.1M in total assets as of fiscal year 2025, including both current and long-term assets.

How much does Anixa Biosciences, Inc. spend on research and development?

Anixa Biosciences, Inc. (ANIX) invested $5.1M in research and development during fiscal year 2025.

How many shares does Anixa Biosciences, Inc. have outstanding?

Anixa Biosciences, Inc. (ANIX) had 33M shares outstanding as of fiscal year 2025.

What is Anixa Biosciences, Inc.'s current ratio?

Anixa Biosciences, Inc. (ANIX) had a current ratio of 8.08 as of fiscal year 2025, which is generally considered healthy.

What is Anixa Biosciences, Inc.'s debt-to-equity ratio?

Anixa Biosciences, Inc. (ANIX) had a debt-to-equity ratio of 0.14 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Anixa Biosciences, Inc.'s return on assets (ROA)?

Anixa Biosciences, Inc. (ANIX) had a return on assets of -68.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Anixa Biosciences, Inc.'s P/E ratio?

Anixa Biosciences, Inc. (ANIX) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $100.8M as of Oct 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Anixa Biosciences, Inc.'s price-to-sales ratio?

Anixa Biosciences, Inc. (ANIX) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $100.8M as of Oct 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

How does Anixa Biosciences, Inc.'s liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, Anixa Biosciences, Inc. (ANIX) held $15.2M in cash, cash equivalents and investments, and reported an operating cash outflow of $7.2M over that year. Dividing the one by the other, the reported balance equals about 25 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is Anixa Biosciences, Inc.'s Piotroski F-Score?

Anixa Biosciences, Inc. (ANIX) has a Piotroski F-Score of 1 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Anixa Biosciences, Inc.'s earnings high quality?

Anixa Biosciences, Inc. (ANIX) reported a net loss of $10.9M while operations used $7.2M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.